Home Applications 213491 Application 213491
Type NDA
Sponsor HORIZON PHARMA USA Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 PROCYSBI CYSTEAMINE BITARTRATE GRANULE;ORAL EQ 75MG BASE/PACKET Yes No 002 PROCYSBI CYSTEAMINE BITARTRATE GRANULE;ORAL EQ 300MG BASE/PACKET Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213491-001 PROCYSBI CYSTEAMINE BITARTRATE EQ 75MG BASE/PACKET GRANULE, DELAYED RELEASE / ORAL RLD 2020-02-14 N213491-002 PROCYSBI CYSTEAMINE BITARTRATE EQ 300MG BASE/PACKET GRANULE, DELAYED RELEASE / ORAL RLD, RS 2020-02-14
Orange Book patents# Current patent rows page 1 of 1 · 48 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 3 of 3 · 82 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213491-001 PROCYSBI EQ 75MG BASE/PACKET GRANULE, DELAYED RELEASE / ORAL RLD 2020-02-14 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213491-002 PROCYSBI EQ 300MG BASE/PACKET GRANULE, DELAYED RELEASE / ORAL RLD, RS 2020-02-14 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 45 · 1,782 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N213491-001 9192590 2027-01-26 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9198882 2027-01-26 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9925156 2027-01-26 U-1399 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9925157 2027-01-26 U-1399 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9925158 2027-01-26 U-1399 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9192590*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9198882*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9925156*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9925157*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9925158*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 8026284 2027-09-22 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 8026284*PED 2028-03-22 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9173851 2034-06-17 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9233077 2034-06-17 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9173851*PED 2034-12-17 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 9233077*PED 2034-12-17 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 10143665 2036-08-16 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 10328037 2036-08-16 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 10548859 2036-08-16 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 10905662 2036-08-16 U-1399 2021-03-02 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 10143665*PED 2037-02-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 10328037*PED 2037-02-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 10548859*PED 2037-02-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-001 10905662*PED 2037-02-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9192590 2027-01-26 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9198882 2027-01-26 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9925156 2027-01-26 U-1399 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9925157 2027-01-26 U-1399 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9925158 2027-01-26 U-1399 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9192590*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9198882*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9925156*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9925157*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9925158*PED 2027-07-26 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 8026284 2027-09-22 U-1399 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 8026284*PED 2028-03-22 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9173851 2034-06-17 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9233077 2034-06-17 Drug product 2020-03-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9173851*PED 2034-12-17 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213491-002 9233077*PED 2034-12-17 Pediatric extension d4dbc9d85df4…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 6 · 216 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 10 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 75987-140 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-140 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-140 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-140 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-140 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-145 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-145 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-145 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-145 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current 75987-145 PROCYSBI Cysteamine bitartrate Horizon Therapeutics USA, Inc. NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 70166 SUPPL 2022-02-15 70158 SUPPL 2022-02-14 63335 ORIG 2020-05-29 61912 ORIG 2020-02-19 61906 ORIG 2020-02-18